Blinatumomab 38.5micrograms powder and solution for solution for infusion vials
NHS hospitals in England used £39,780,807 of indicative cost of Blinatumomab 38.5micrograms powder and solution for solution for infusion vials in the 12 months to April 2026, about 0.2% of all hospital medicines spend. That is up 4.0% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Blinatumomab 38.5micrograms powder and solution for solution for infusion vials: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to April 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Blinatumomab 38.5micrograms powder and solution for solution for infusion vials most
By indicative cost over the 12 months to April 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| University College London Foundation Tr | £4,453,637 |
| North West Anglia Nhs Foundation Trust | £3,393,018 |
| The Royal Marsden Nhs Foundation Trust | £3,152,571 |
| Univ Hpls Bristol Nhs Foundation Trust | £2,450,655 |
| The Newcastle Upon Tyne Hpl Nhs Found Tr | £2,271,142 |
| Nottingham University Hospitals Trust | £2,248,955 |
| Univ Hpl B/Ham Nhs Foundation Trust | £2,000,864 |
| King's College Hpl Nhs Foundation Trust | £1,649,967 |
| University Hospital Southampton Nhs Ft | £1,643,855 |
| Cambridge Univ Hosp Nhs Foundation Trust | £1,599,481 |
The primary-care picture
No confident match to a community-dispensed medicine was found for this product, so no primary-care comparison is shown. SCMD products are recorded at product level, which does not always map cleanly to a BNF substance.